Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement studies peer review

This article was originally published in The Tan Sheet

Executive Summary

The American Journal of Clinical Nutrition announces submission and review guidelines for studies involving dietary supplements. Manuscripts will undergo initial review by at least two editorial board members, who will advise AJCN's editor on suitability for full peer review by evaluating scientific excellence, comprehensiveness and relevance to the field of clinical nutrition. Papers regarding the clinical use of supplements in the context of diet or a diet-related disease will be viewed as appropriate. Review papers on supplements or nutraceuticals will be eligible for peer review and potential publication "if they are found to be both comprehensive and balanced, to deal with all issues of biological and clinical efficacy and safety, and to be of significance to the field of clinical nutrition"

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel